SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...

Dexcom announced last week that its G7 continuous glucose monitoring system has received FDA clearance. The latest model of its CGM, which can be used by people with all types of diabetes ages 2 and ...

One of medtech’s most anticipated devices has won approval in Europe. Dexcom has received CE mark for its long-awaited G7 Continuous Glucose Monitoring System for people with diabetes in age two years ...

Dexcom is in seventh heaven: A year after its initial FDA submission, the diabetes tech maker has finally gotten the green light to begin rolling out its latest continuous glucose monitor system in ...

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE ...

Dexcom G7 is the most accurate CGM system1 approved by Health Canada, building on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hypoglycemia, and improve time ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...

The Dexcom G7 continuous glucose monitoring (CGM) system has been granted a CE Mark (Conformité Européenne), which means it is approved for use in people with diabetes in Europe aged 2 years and older ...